Twist Bioscience secures $50m to advance DNA Synthesis Platform

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Antiv3D)
(Image: Getty/Antiv3D)
The synthetic DNA provider Twist Bioscience Corporation has completed a private placement of $50m to advance its proprietary, silicon-based DNA Synthesis Platform.

The San Francisco, CA-based company plans to invest part of the funds in “the emerging vertical market opportunity presented by storing digital data in DNA”​ as well as “forward integration toward drug discovery,” ​said Twist Bioscience CEO Emily M. Leproust, PhD.

The company has raised $259m since its inception in 2013 and has seen an increase in demand across several areas where companies use its services, Leproust told us.

This includes pharmaceuticals/biotech customers who use the platform to support the drug discovery process as well as next-generation sequencing for target enrichment and detection of disease-causing genetic variations, she said.

“We have used our proprietary DNA synthesis platform, which delivers precision at a scale previously not available, to develop a portfolio of diverse products for two large market opportunities – the synthetic biology market through our gene and oligo pool offerings, and the next-generation sequencing market through our exome and custom target enrichment solutions,”​ Leproust explained in the press release.

Twist Bioscience has a second site in South San Francisco and international offices in Tel Aviv, Israel. In February, the company opened a new 2,500 square-foot office space in the San Diego, CA area.

The company also in February announced the commercial availability of several new products to enhance next-generation sequencing, including its Twist Human Core Exome Kit and its Custom Panels offering.

As of February, the company had shipped more than 150,000 genes in the last 12 months.

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us


View more